Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Epilepsy
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Epilepsy
    TopAbstracts in Epilepsy 06/25/2009 - (DGNews)
    TopAbstracts in Epilepsy 06/11/2009 - (DGNews)
    FDA Approves Once-Daily Extended Release Lamotrigine for Epilepsy - (DGNews)
    TopAbstracts in Epilepsy 05/28/2009 - (DGNews)
    TopAbstracts in Epilepsy 05/14/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Epilepsy
  • Some Anti-Epileptic Drugs May Compromise Bone Health
  • Balancing Treatment With Reproductive Health in Women With Epilepsy
  • Understanding the Ramifications of Switching Among AED's: A 2008 Clinical Update

    Webcasts/CME archive

     Recent cases - Epilepsy
      Diarrhea, Negative T-Waves, Fever and Skin Rash, Rare Manifestation of Carbamazepine Hypersensitivity: A Case Report
      Syncope Due to Asystole During Epilepsy. A Case Report
      Lennox Gastaut Syndrome, Review of the Literature and a Case Report
      Partial Trisomy 13q22-qter Associated to Leukoencephalopathy and Late Onset Generalised Epilepsy
      Probable Causal Link Between Epilepsy and Sleep Apnea: Case Report

      Cases archive
        




      my personal edition > epilepsy > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Levetiracetam Appears Effective in Juvenile Myoclonic Epilepsy: Presented at AES

      By Howard Fenton

      WASHINGTON, DC -- December 8, 2005 -- In a retrospective study, 26 of 30 children suffering from juvenile myoclonic epilepsy were either seizure-free or achieved a 50% reduction in seizures by taking the anti-epileptic agent levetiracetam (Keppra).

      "Levetiracetam appears useful as a first-line agent in the treatment of juvenile myoclonic epilepsy," said Deron Sharpe, MD, Pediatric Neurologist, Vanderbilt University Medical Center, Nashville, Tennessee, United States.

      Dr. Sharpe and colleagues analysed the records of 11 patients diagnosed with certain juvenile myoclonic epilepsy and 19 with probably juvenile myoclonic epilepsy. Sixteen of the patients were not on any appropriate anti-epileptic therapy; 10 were taking valproate and four were on other medications.

      In a poster presentation at the annual joint meeting of the American Epilepsy Society (AES) and the American Clinical Neurophysiology society, Dr. Sharpe said that in the follow-up period of about 1 to 3 years, 24 of the patients or 80% of the total were seizure free; two other patients had their seizures reduced by 50% or more, giving a total of an 86.7% response rate to the drug.

      The 10 patients whose seizures were controlled with valproate were successfully weaned from that drug and onto levetiracetam.

      One patient discontinued levetiracetam because of mood alterations after being free of seizures for 14 months. Mild mood fluctuations occurred in a second patient who stayed on treatment with levetiracetam and remains seizure free. There were no other adverse events, Dr. Sharpe said in his presentation December 5th.

      "The favorable results in this retrospective study should be confirmed in larger, prospective trials of patients with newly diagnosed juvenile myoclonic epilepsy," he said.

      The trial was partially funded by UCB Pharma, Inc., which markets Keppra.


      [Presentation title: Use of Levetiracetam in Juvenile Myoclonic Epilepsy. Abstract 2.333]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send